Physician profile
James Christopher Pappas
NPI 1710928148
$780.36
in general payments reported to CMS, 2019-2025
16 companies · $63.07 in 2025
The $63.07 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $16.60 · 2021: $12.60 · 2022: $65.55 · 2023: $21.14 · 2024: $58.33 · 2025: $63.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $204.55 | 2019-2025 | Briviact |
| Sunovion Pharmaceuticals INC. | $80.38 | 2019 | |
| Livanova USA, INC. | $71.85 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $61.49 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $57.61 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $55.82 | 2019-2025 | |
| Biomarin Pharmaceutical INC. | $40.40 | 2019 | |
| Greenwich Biosciences, INC. | $38.89 | 2019 | |
| Eisai INC. | $33.53 | 2019 | |
| Sk Life Science, INC. | $26.27 | 2022 | |
| Acadia Pharmaceuticals INC | $21.14 | 2023 | Daybue |
| Lundbeck LLC | $20.52 | 2019 | |
| Kedrion Biopharma INC. | $19.95 | 2019 | |
| Ptc Therapeutics, INC. | $18.76 | 2019 | |
| Currax Pharmaceuticals LLC | $16.60 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pappas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.